AGTX (Agentix) Buyback Yield %: 0.00 (As of Jul. 13, 2026)


What is Agentix Buyback Yield %?

Agentix AGTX Buyback Yield % is 0.00 as of Jul. 13, 2026. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, Agentix ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Agentix's current buyback yield was 0.00%.

Agentix Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Agentix's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agentix Buyback Yield % Chart

Agentix Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23 Mar24 Mar25 Mar26
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.74 -1.25 0.00 0.00 0.00

Agentix Quarterly Data
May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AGTX vs BZYR, ATXI, EMMA: Buyback Yield % Comparison

For the Biotechnology subindustry, Agentix's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Agentix's Buyback Yield % falls into.


Agentix Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Agentix's Buyback Yield for the fiscal year that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 1.682814
=0.00%

Agentix's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 1.682814
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Agentix (AGTX) has a Buyback Yield % of 0.00 as of Jul. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Agentix and its competitors. According to the industry distribution chart, Agentix ranks #999999 out of 742 companies in the Biotechnology industry.
Is Agentix's Buyback Yield % too high?
Agentix's current Buyback Yield % is 0.00. Based on the distribution chart, Agentix ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Agentix's Buyback Yield % compare to BZYR and ATXI?
According to the Biotechnology industry distribution chart, Agentix ranks #999999 out of 742 companies for Buyback Yield %. This places Agentix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Agentix and its competitors. Agentix's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agentix stock overvalued right now?
Agentix (AGTX) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Agentix (AGTX), the current Buyback Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Agentix Business Description

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.